Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UPROOT study of obinutuzumab in primary Sjögren's syndrome
2024-519884-16-00Phase 2Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab in primary Sjögren's syndrome, sponsored by Radboud University Medical Center. Primary endpoint: Autoreactive B-cell depletion at 3 months. Planned start Mar 2026; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2024-519884-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519884-16-00.